Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies

Annals of Surgery

Volumn 259, Issue 6, 2014, Pages 1215-1222

  Rueth, Natasha M ^a   Xing, Yan ^a   Chiang, Yi Ju ^a   Cromwell, Kate D ^a   Ross, Merrick I ^a   Lee, Jeffrey E ^a   Gershenwald, Jeffrey E ^a   Royal, Richard E ^a   Cormier, Janice N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cost effectiveness; Melanoma; Recurrence; Surveillance; Survival

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL DECISION MAKING; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MELANOMA; PREDICTIVE VALUE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DERMATOLOGIC SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; SEER PROGRAM; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84900860080     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000233     Document Type: Article

References (44)

1. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666-1674
2. Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520-529
3. Benvenuto-Andrade C, Oseitutu A, Agero AL, et al. Cutaneous melanoma: Surveillance of patients for recurrence and new primary melanomas. Dermatol Ther. 2005;18:423-435
4. Rhodes AR. Cutaneous melanoma and intervention strategies to reduce tumorrelated mortality: What we know, what we don't know, and what we think we know that isn't so. Dermatol Ther. 2006;19:50-69
5. Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133:104-110
6. Young SE, Martinez SR, Essner R. The role of surgery in treatment of stage IV melanoma. J Surg Oncol. 2006;94:344-351
7. Riker AI, Kirksey L, Thompson L, et al. Current surgical management of melanoma. Expert Rev Anticancer Ther. 2006;6:1569-1583
8. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based?. Ann Surg. 1995;221:566-569
9. Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer. 1999;86:2252-2258
10. Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Br J Dermatol. 1999;140:249-254
11. Baughan CA, Hall VL, Leppard BJ, et al. Follow-up in stage I cutaneous malignant melanoma: An audit. Clin Oncol (R Coll Radiol). 1993;5:174-180
12. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703-1705
13. Sylaidis P, Gordon D, Rigby H, et al. Follow-up requirements for thick cutaneous melanoma. Br J Plast Surg. 1997;50:349-353
14. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. http://www.nccn.org. Accessed September 18, 2013
15. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608-621
16. ProvostN,Marghoob AA,KopfAW, et al. Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: A survey of experienced physicians. J Am Acad Dermatol. 1997;36:711-720
17. Kuntz KM. Can mathematical modeling remove the tarnish on old clinical trials?. Am J Med. 2001;111:155-156
18. Cormier JN, Xing Y, Ding M, et al. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007;25:2442-2448
19. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making. 1993;13:322-338
20. Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67:228-233
21. Tafra L, Dale PS, Wanek LA, et al. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thoracic Cardiovasc Surg. 1995;110:119-128
22. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6: 9-17
23. Arias E. United States Life Tables. National Vital Statistics Reports (NVSS). Vol 51. Department of Health and Human Services Centers for Disease Control and Prevention; 2000:1-42
24. American Joint Committee on Cancer. In: Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Handbook. New York: Springer; 2002:421
25. Collett D. Modelling Survival Data in Medical Research. London: Chapman & Hall; 1994
26. Gerdtham UG, Zethraeus N. Predicting survival in cost-effectiveness analyses based on clinical trials. Int J Technol Assess Health Care. 2003;19:507-512
27. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imagingmodalities for the staging and surveillance of melanoma patients: A meta-Analysis. J Natl Cancer Inst. 2011;103:129-142
28. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206
29. Leiter U,Meier F, Schittek B, et al. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172-178
30. MacCormack MA, Cohen LM, Rogers GS. Local melanoma recurrence: A clarification of terminology. Dermatol Surg. 2004;30:1533-1538
31. Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: Analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19:2547-2555
32. Romano E, ScordoM, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: Implications for follow-up guidelines. J Clin Oncol. 2010;28:3042-3047
33. Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680 000 people exposed to computed tomography scans in childhood or adolescence: Data linkage study of 11 million Australians. BMJ. 2013;346:f2360
34. Miglioretti DL, Johnson E,Williams A, et al. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr. 2013;167:700-707
35. Goodman DM. Initiatives focus on limiting radiation exposure to patients during CT scans. JAMA. 2013;309:647-648
36. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151-157
37. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology. 1995;191:199-203
38. Hengge UR, Wallerand A, Stutzki A, et al. Cost-effectiveness of reduced follow-up in malignant melanoma. J Dtsch Dermatol Ges. 2007;5:898-907
39. Bastiaannet E, Uyl-de Groot CA, Brouwers AH, et al. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg. 2012;255:771-776
40. Kroon BB. Surgery for distant metastatic melanoma improves survival. Ann Surg Oncol. 2012;19:2426-2427
41. Rychetnik L, McCaffery K, Morton R, et al. Psychosocial aspects of posttreatment follow-up for stage I/II melanoma: A systematic review of the literature. Psychooncology. 2013;22:721-736
42. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677
43. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516
44. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.